In patients with locally advanced non-small cell lung cancer (NSCLC), the addition of drugs oleclumab or monalizumab to durvalumab improved progression-free survival, said researchers.
The data is part of the COAST trial and will be presented at the annual meeting of the European Society for Medical Oncology (ESMO).
"Our results from the COAST trial are very encouraging as the data suggest these novel immunotherapy drug combinations could improve clinical outcomes for patients with advanced NSCLC," said Roy S....
In patients with locally advanced non-small cell lung cancer (NSCLC), the addition of drugs oleclumab or monalizumab to durvalumab improved progression-free survival, said researchers.
The data is part of the COAST trial and will be presented at the annual meeting of the European Society for Medical Oncology (ESMO).
"Our results from the COAST trial are very encouraging as the data suggest these novel immunotherapy drug combinations could improve clinical outcomes for patients with advanced NSCLC," said Roy S....